Beam Therapeutics Inc.
Beam Therapeutics Inc. is listed today as Beam Therapeutics Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2018 | $135 M | No. 2 | $50 to $250 million | equity | SEC | |
| Feb 2018 | $84 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Beam Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2019).
SEC Form D · Mar 2019
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2019
That is all the official record says: Beam Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Beam Therapeutics Inc. are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| ARCH Venture Fund IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| ARCH Venture Partners IX, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| ARCH Venture Partners IX, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| ARCH Venture Partners IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Fmr LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Mark Fishman | Person | not stated | not stated | Held Series A-1 preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Redmile Group, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 27 investors.
Largest shareholders today
Institutions holding Beam Therapeutics Inc. shares, as of Sep 30, 2026.
- FMR LLC$316 M12.49%
- ARK Investment Management LLC$289 M11.41%
- Farallon Capital Management, L.L.C.$251 M9.93%
- BlackRock, Inc.$223 M8.81%
- State Street Corp$145 M5.72%
- Vanguard Portfolio Management LLC$120 M4.74%
- Vanguard Capital Management LLC$113 M4.45%
- ARCH Venture Management, LLC$111 M4.39%
- Kynam Capital Management, LP$96 M3.80%
- Sumitomo Mitsui Trust Group, Inc.$82 M3.24%
- Amova Asset Management Americas, Inc.$82 M3.24%
- Geode Capital Management, LLC$61 M2.43%
- Price T Rowe Associates Inc /MD/$53 M2.11%
- Dimensional Fund Advisors LP$53 M2.09%
- Morgan Stanley$48 M1.90%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| John Evans | Executive officer | Mar 2019 |
| Carole Ho | Director | Mar 2019 |
| John Evans | Director | Mar 2019 |
| Kristina Burow | Director | Mar 2019 |
| Mark Fishman | Director | Mar 2019 |
| Michael Yi | Director | Mar 2019 |
| Robert Nelsen | Director | Mar 2019 |
| Stephen Knight | Director | Mar 2019 |
| Feng Zhang | Director | Aug 2018 |
| Robert Nelson | Director | Aug 2018 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.